Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Incyte Corporation

INCY
Current price
58.21 USD +0.48 USD (+0.83%)
Last closed 60.29 USD
ISIN US45337C1027
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 11 265 032 192 USD
Yield for 12 month +12.11 %
1Y
3Y
5Y
10Y
15Y
INCY
21.11.2021 - 28.11.2021

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

73.40 USD

P/E ratio

388.07

Dividend Yield

Current Year

+4 241 217 000 USD

Last Year

+3 695 649 000 USD

Current Quarter

+1 178 698 000 USD

Last Quarter

+1 137 871 000 USD

Current Year

+3 929 149 000 USD

Last Year

+3 440 649 000 USD

Current Quarter

+1 090 198 000 USD

Last Quarter

+1 051 871 000 USD

Key Figures INCY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 177 596 992 USD
Operating Margin TTM 25.34 %
Price to Earnings 388.07
Return On Assets TTM 0.86 %
PEG Ratio 0.37
Return On Equity TTM 0.75 %
Wall Street Target Price 73.40 USD
Revenue TTM 4 241 217 024 USD
Book Value 17.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 16.30 %
Dividend Yield
Gross Profit TTM 1 484 626 048 USD
Earnings per share 0.15 USD
Diluted Eps TTM 0.15 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY 14.30 %
Profit Margin 0.77 %

Dividend Analytics INCY

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History INCY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 2:1
Payout Ratio
Last Split Date 01.09.2000

Stock Valuation INCY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 388.07
Forward PE 9.62
Enterprise Value Revenue 2.16
Price Sales TTM 2.66
Enterprise Value EBITDA 22.42
Price Book MRQ 3.27

Financials INCY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators INCY

For 52 weeks

50.35 USD 83.95 USD
50 Day MA 65.63 USD
Shares Short Prior Month 6 359 808
200 Day MA 67.66 USD
Short Ratio 3.42
Shares Short 7 190 582
Short Percent 6.58 %